Manuel Battegay

发表

The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients

Huldrych F. Günthard, Niko Beerenwinkel, Matthias Cavassini, 2013, PLoS Comput. Biol..

SPHN/PHRT: Forming a Swiss-Wide Infrastructure for Data-Driven Sepsis Research

Gunnar Rätsch, Karsten Borgwardt, Peter Bühlmann, 2020, MIE.

Introduction to Machine Learning in Digital Healthcare Epidemiology

Julia E. Vogt, Manuel Battegay, Jan A Roth, 2018, Infection Control & Hospital Epidemiology.

Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study

Huldrych F. Günthard, Matthias Cavassini, Manuel Battegay, 2021, PLoS Comput. Biol..

Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.

Amalio Telenti, Hansjakob Furrer, Manuel Battegay, 2002, AIDS.

Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection

Victor Greiff, Manuel Battegay, Sai T Reddy, 2015, Human vaccines & immunotherapeutics.

Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study

Jim Young, Amalio Telenti, Hansjakob Furrer, 2004, BMJ : British Medical Journal.

Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals: A Longitudinal Study

Matthias Cavassini, Patrick Taffé, Amalio Telenti, 2009, Circulation. Cardiovascular genetics.

Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland.

Matthias Cavassini, Patrick Taffé, Sebastian Bonhoeffer, 2010, The Journal of infectious diseases.

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

Hansjakob Furrer, Manuel Battegay, Pietro Vernazza, 2019, The Lancet.

Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population

Amalio Telenti, Manuel Battegay, Bernard Hirschel, 2003, The Lancet.

Highly Active Antiretroviral Therapy

Amiram Gafni, Manuel Battegay, Andrew J. Palmer, 2012, PharmacoEconomics.

Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study

Manuel Battegay, Andreas F Widmer, M. Battegay, 2007, BMC infectious diseases.

CD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and Switzerland.

Patrick Taffé, Manuel Battegay, Matthias Egger, 2009, The Journal of infectious diseases.

Estimating the Net Contribution of Interleukin-28B Variation to Spontaneous Hepatitis C Virus Clearance

Jacques Fellay, Dermot Kelleher, Amalio Telenti, 2011, Hepatology.

Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country

Hansjakob Furrer, Manuel Battegay, Jacques Schrenzel, 2016, Journal of Clinical Microbiology.

Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.

Wei Zhang, Manuel Battegay, Sreeraj Macha, 2011, Clinical therapeutics.

Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus.

Manuel Battegay, Catia Marzolini, M. Battegay, 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection

Beda Joos, Huldrych F. Günthard, Matthias Cavassini, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study

Manuel Battegay, Thomas Klimkait, Christoph Schaefer, 2002, The Lancet.

TB in a low-incidence country: differences between new immigrants, foreign-born residents and native residents.

Manuel Battegay, Andreas F Widmer, M. Battegay, 2007, The American journal of medicine.

Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern

Manuel Battegay, Thomas Klimkait, Hansjakob Furrer, 2016, AIDS.

Erratum: Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection (Journal of Virology (2006) 80, 22, (11094-11104))

Amalio Telenti, Hansjakob Furrer, Manuel Battegay, 2007 .

Correlates of Self-Reported Nonadherence to Antiretroviral Therapy in HIV-Infected Patients: The Swiss HIV Cohort Study

Matthias Cavassini, Hansjakob Furrer, Manuel Battegay, 2006, Journal of acquired immune deficiency syndromes.

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.

Sven Bergmann, Thomas Berg, Zoltán Kutalik, 2010, Gastroenterology.

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study

Manuel Battegay, Bernard Hirschel, Pietro Vernazza, 1997, BMJ.

Optimising the performance of an outpatient setting.

Manuel Battegay, Maiwenn J Al, Pedram Sendi, 2004, Swiss medical weekly.

Self-Reported Non-Adherence to Antiretroviral Therapy Repeatedly assessed by Two Questions Predicts Treatment Failure in Virologically Suppressed Patients

Hansjakob Furrer, Manuel Battegay, Bernard Hirschel, 2008, Antiviral therapy.